University College London Hospitals Collaborate with AstraZeneca and IgniteData to Test SMART ON FHIR Based Tech
University College London Hospitals NHS Foundation Trust, IgniteData and AstraZeneca have successfully gone live in non-production (a mirror image of the live health record with synthetic non-sensitive patient data) testing with IgniteData’s HL7 FHIR enabled clinical trial data transfer platform, Archer. Testing will be conducted on UCLH’s Epic non-production EHR, before going live during Q4 2021 to automate the transfer of data into AstraZeneca’s Medidata Rave for an oncology study.
During 2022, IgniteData will collaborate with AstraZeneca to scale the standardized technology to other NHS and European hospitals. Archer is supervised by the investigator, meaning they maintain full control of which data leaves the hospital and no sensitive data is retained by Archer.
The project does not involve any new sharing of data, beyond the planned data sharing that will occur in the oncology research study. The work with Archer aims to improve the way in which data is transferred between systems.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
